In type 2 diabetes with CKD and additional CV risk factors, sotagliflozin reduced total MACE vs. placebo at a median 14 mo - KIVIRID

In type 2 diabetes with CKD and additional CV risk factors, sotagliflozin reduced total MACE vs. placebo at a median 14 mo

Authors: Aarti Thakkar, L. Kristin Newby,

Published: 2025-06-02

DOI: 10.7326/annals-25-01791-jc

Source: Full article

Abstract

No abstract found.